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Several  characteristics  of human  eosinophil  heterogeneity  in  some  diseases 
associated  with  eosinophilia  have  been  reported.  They  concerned  eosinophil 
morphology with reduced numbers of granules and increased membrane recep- 
tors (1),  cell  density, and  cytotoxic functions (2) or metabolism  (3).  The  more 
interesting  topic  related  to  this  point  is  the  functional  role  of these  altered 
eosinophils in human pathology, as suspected in a variety of diseases characterized 
mainly by cardiac or lung injury (4). Our previous works showed that the presence 
of receptors for IgE (FcE receptors), directly involved in the effector function of 
human  eosinophils against  IgE-coated parasite  targets,  was restricted  to a  sub- 
population  of eosinophils (5).  This eosinophil subpopulation of abnormally low 
density, named for this reason "hypodense" (2), was only present in the blood of 
highly  hypereosinophilic  patients  (eosinophil  counts  >3,000/mm 3)  or  in  the 
tissues,  mainly  in  some cases of lung diseases (6).  In  addition,  a  recent  report 
indicating  that  pulmonary  eosinophils  could  kill  lung  parenchymal  cells  (7), 
suggested  a  particularly  effective  function  of these  eosinophils,  not  only  in 
antiparasite cytotoxicity but also in various pathological situations. 
Like eosinophils, human  platelets were discovered to be effector cells against 
schistosomula ofSchistosoma  mansoni, in vitro and in vivo, in the presence of IgE 
antibodies  (8).  Both mechanisms  of killing  involved  Fce receptors,  which  bind 
IgE  immunoglobulins  with  a  relatively  low affinity  (9).  Antigenic  similarities 
between FceR of eosinophils and platelets were suggested by the parallel  inhibi- 
tion of both  IgE-dependent  cytotoxicity and  IgE binding,  with polyclonal anti- 
bodies also able to inhibit Fc~R on human lymphocytes and monocytes (5, 9-1 1). 
The  original  aim  of this  study was to prepare  an  mAb specifically directed 
against the bypodense subpopulation of human  eosinophils in  order to obtain a 
phenotypic marker  that  could characterize  and quantify these cells both in  the 
blood and  tissues  of hypereosinophilic  patients.  Moreover,  since  recent  data 
suggested that  these hypogranular  cells were activated in vivo (6), the presence 
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of such  a  marker could  be  useful  in  following activation and/or  maturation  of 
eosinophits.  We  report  here  on  an  IgM  mAb  named  BB10  raised  against 
hypodense  blood  and  lung  eosinophils,  which  turns  out  to  be  an  antibody  to 
FceR of eosinophits, platelets, and macrophages (Fc,R2). 
Materials and  Methods 
Preparation  of mAbs.  Balb/c  mice  were  immunized  with  two  doses  of  107  human 
eosinophils at 3 wk intervals, in the presence of CFA. Hypodense blood eosinophils were 
used  for immunization and  were purified as described below  ("cell  purification"). The 
first immunization was given subcutaneously and the second intraperitoneally. 2 wk after 
the second injection, animals were bled and a first control on this polyclonal antiserum 
was performed. 3 d before the hybridization, two mice were boosted intravenously with 
5 ×  I 06 lung eosinophils obtained by bronchoalveolar lavage. 
For hybridization, spleen  cells were removed and fused with the SP20  myeloma cell 
line, using PEG and DMSO according to the technique previously described (12). Culture 
supernatants  were tested  by indirect  fluorescence,  using human  eosinophils coated on 
microscope slides,  according  to  the  immunofluorescence slide  assay (IFSA) 1 technique 
detailed below (13).  Among  11  hybridoma cultures containing antibodies reacting with 
eosinophils,  three  were  selected  and  cloned  twice  by the  limiting dilution  technique. 
Subsequently, the clones were injected subcutaneously into BALB/c mice to induce solid 
tumors.  After homogenization of these  tumors, cells were injected  into  the  peritoneal 
cavities of BALB/c mice; the ascitic fluids were collected 2 wk later and assayed by indirect 
fluorescence on various cell populations. One given clone (named BB10) was selected for 
further  investigation.  This  BB10  mAb  was  found  to  be  an  IgM  immunoglobulin  by 
Ouchterlony analysis using antimouse immunoglobulins antisera  (Bionetics  Laboratory 
Products, Charleston, SC). 
A second mouse IgM mAb (G 10-54) with a different specificity was used as a control 
in  all  the  experiments.  It  was  obtained,  by a  procedure  similar  to  that  used  for  the 
preparation of BB 10, from mice immunized with a soluble antigenic extract of Echinococcus 
multilocularis. 
Purification oflgM Fraction.  The same procedure was used to purify the tgM fraction 
of BB 10 and control G10-54. Ascitic fluids from mice injected with either BB10 or G10- 
54  tumor cells were  submitted  to gel filtration  using ACA34  gel  (IBF,  Villeneuve-La- 
Garenne,  France) and  K50/100 column (Pharmacia Fine Chemicals, Uppsala, Sweden). 
The IgM fractions were stored at +4°C, at a concentration of 2 mg/ml, without further 
dialysis. 
Celt Purification.  Human eosinophils were purified from the venous blood of patients 
with hypereosinophilia of various etiologies by centrifugation upon discontinuous metri- 
zamide gradients (Nyegaard, Oslo,  Norway), according to the technique previously de- 
scribed  (14).  Several  cell  fractions  containing  more  than  85%  pure  eosinophils  were 
collected from the various gradients, according to their density (2). They were referred 
to  as  hypodense  cells  when  obtained  in  the  lower  density  layers,  corresponding  to 
metrizamide concentrations <23% and "normodense" cells when collected from the top 
of the  25%  and  24%  layers.  Lung eosinophils were purified with  the  same procedure 
from bronchoalveolar lavage (BAL) performed under fiber-optic bronchoscopy on patients 
with the pulmonary infiltration with eosinophil (PIE) syndrome (I 5).  For mice immuni- 
zation, hypodense blood and lung eosinophils from the same patient with hypereosino- 
philia-associated drug hypersensitivity were used. Human monocytes and neutrophils were 
purified by the same technique,  from peripheral blood leucocytes of normal or slightly 
hypereosinophilic patients.  They were recovered respectively from the top of the  18% 
step for monocytes, and from the top of the 22% and 23% steps for neutrophils (14). 
t Abbreviations used in  this paper:  BAL, bronchoalveolar  lavage; DMSI, dimethylsuberimidate; 
FMF, flow microfluorometry;  IFSA, immunofluorescence slide assay; MEM/FCS, minimum essential 
medium supplemented with FCS; NRS, normal rat serum; PGE1, prostaglandine El; PIE, puhnonary 
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Washed human platelets were purified from venous blood of normal subjects collected 
on  citric  acid/dextrose  medium, and  platelet-rich plasma was washed  in  saline supple- 
mented with citric acid (36 raM), glucose (5 mM), calcium (2 raM), magnesium (1  raM), 
BSA (0.35%), and prostaglandin  E1  (PGEI) (100 riM), according to a previous technique 
(16).  Alveolar macrophages were obtained from non hypereosinophilic patients by BAL, 
and  the  alveolar cell  population,  consisting  of nearly  80%  alveolar macrophages, was 
washed as reported earlier (17). 
Rat peritoneal cells were purified by a method of centrifugation through discontinuous 
Percoll gradients, adapted from the technique used for human eosinophils (18).  Briefly, a 
Percoll solution (Pharmacia Fine Chemicals) was diluted to obtain the following densities: 
1.105,  1.095,  1.085,  1.080,  1.075,  1.065.  2 ml of each solution were layered on top of 
each other.  The peritoneal cell suspensions stimulated  48  h  previously by injection  of 
0.9% sterile physiological saline were obtained from normal rats, and were suspended in 
minimum  essential  medium  supplemented  with  1%  heat-inactivated  normal  rat  serum 
(MEM/NRS) at a concentration of 25 X 106/ml. 2 ml of the cell suspension were layered 
over the  Percoll gradient and the  tubes were then spun at 400 g at +4°C  for 60  rain. 
Cytocentrifuge smears were prepared  for differential counts and stained  with  Giemsa. 
Eosinophils (>80%  purity)  were  recovered at  the  interface between  the  layers of 0  = 
1.095 and O =  1.085,  whereas macrophages (>90% purity) were obtained at the density 
layer of 1.065.  Lymphocytes were obtained fi'om mesenteric lymph nodes of normal rats, 
according to previously described techniques (19).  Purified mast cells (>90% purity) were 
recovered after centrifugation  of normal  rat peritoneal  cells  over 22.5%  metrizamide 
(19). 
Human cell lines were maintained in  RPMI  1640 (Gibco Laboratories, Grand Island, 
NY) supplemented with  10% heat-inactivated FCS. Two U937 cell lines varying in their 
IgE binding capacity were donated by Dr. B. Stadler (Instit/it ffir Klinische lmmiinologie, 
Inselspital, Bern, Switzerland) and Dr. R. Van Furth (Department of Microbial Diseases, 
University Hospital, Leiden, Netherlands). 
Reagents.  Highly purified human  IgE myeloma protein (P.S.)  was kindly donated by 
Dr.  H.  L.  Spiegelberg (Scripps  Clinic,  La Jolla,  CA).  Human  IgG was  purified  from 
normal human serum by ion exchange chromatography. Rat IgE myeloma protein was 
obtained from Dr. Bazin (Louvain University, Brussels, Belgium). For competition exper- 
iments, IgE was previously aggregated with dimethyl suberimidate (DMSI) (5).  Fluores- 
cein-labeled F(ab')2 fragment of antimouse IgG and IgM goat antisera were purchased 
from Cappel Laboratories (Cochranville,  PA).  A goat antiserum directed against a  lym- 
phoblastoid B cell line and able to inhibit Fc~R of lymphocytes and monocytes was kindly 
donated by Dr.  H.  L.  Spiegelberg, Scripps Clinic (11).  An  mAb (BC4) directed against 
the  Fc~ receptor of rat basophilic  leukemia (RBL-2H3) cells  was obtained  from Dr.  R. 
Siraganian (National Institutes of Health, Bethesda, MD). 
Immunofluorescence Slide Assay (IFSA).  Because of the difficulties encountered in  the 
regular supply of eosinophils from hypereosinophilic patients, we adapted a method using 
eosinophils and other cell populations coated on microscope slides (a technique previously 
described for lymphocytes [13]).  To perform the screening of hybridoma supernatants 
Teflon-coated slides (10 reaction areas per slide) were coated overnight at room temper- 
ature with poly-L-lysine (PLL., Sigma Chemical Co., St Louis, MO) at 0.5 mg/ml in PBS. 
After washing with HBSS, 20 ul-aliquots of cell suspensions (106 cells/ml in HBSS without 
protein) were deposited onto each reaction area. After 10 rain at room temperature, the 
coated cells were fixed with glutaraldehyde (0.05% in 0.06 M Sorensen's buffer, pH 7.4) 
for 15 min at room temperature. The slides were then washed with 0.3  M glycin buffer 
in order to block free aldehyde groups. After coating with cells,  the slides  could be kept 
at +4°C in humidified atmosphere for 1 too. Before their use in the fluorescence assay, 
the  degree  of purity  and  the  morphological  aspects  of the  cells  were  verified  using 
interference  contrast  microscopy  (Polyvar,  Reichert,  Federal  Republic  of  Germany). 
Before the addition of reagents, the reaction areas were incubated with HBSS containing 
0.2% gelatin, to avoid nonspecific binding. 
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bated  with  20  gl of the  mAbs (purified  IgM  fractions at  100 gg/ml,  in  HBSS-gelatin). 
After 60 min at room temperature and three washings in HBSS without gelatin, 20 #1 of 
fluorescein-conjugated F(ab'),~  fragment of antimouse  IgM immunoglobulins (1:20 dilu- 
tion in 0.02  M  PBS +  0.2%  gelatin) were added to each reaction area.  The slides were 
then incubated for 30 min at room temperature, in the dark, and washed twice with PBS. 
A  third  washing  with  Evans  blue  diluted  1:10,000  in  PBS  was  performed  to  abolish 
a u to  fluorescence of eosinophil granules. 
Flow Microfluorometry Analysis.  The various cell populations (5 x  106 cells/ml; except 
for platelets,  108/ml) were incubated with BB10 or control G10-54 IgM fractions at 200 
ug/ml (final concentration). After 30 rain of incubation (at room temperature for platelets 
and +4°C for the other cell populations),  the cells were then reacted with FITC-labeled 
anti-mouse IgM antibodies (1:20 dilution for 30 rain). 
After two washings, stained cell suspensions were then analyzed for surface fluorescence 
using an  Ortho Cytofluorograph System  H50 (Ortho  Diagnostic Systems Inc.,  Raritan, 
N  J).  The  results  are  expressed  as  the  percentage  of cells  with  a  fluorescence  intensity 
exceeding the threshold, obtained with the fluorescent reagent only. 
CytotoxicityAssays.  S. mansoni schistosomula prepared according to the skin penetration 
procedure, were the targets of the cytotoxicity assays (20).  For IgE-mediated eosinophil- 
dependent  cytotoxicity,  50-#1  aliquots  of the  schistosomula  suspension  containing  50 
targets in M EM supplemented with 1% heat-inactivated FCS (MEM/FCS), were incubated 
in  flat-bottomed  microtiter  plates  (Nunc,  Roskilde,  Denmark).  50  #1  of unheated  sera 
from S.  mansoni-infected  patients  or  normal  subjects  were added  at a  final  dilution  of 
1:32, together with 100 ~1 ofhypodense eosinophils purified from highly hypereosinophilic 
patients (5,000:1  E/T ratio, according to previous reports) (5).  The IgG-mediated killing 
assay  was  performed  as  previously  described  (14)  with  normodense  eosinophils  from 
slightly  eosinophilic  individuals  and  heat-inactivated  pooled  human  immune  sera,  as  a 
source of IgG antibodies.  For platelet-dependent  cytotoxicity, 50 schistosomula in 80 #1 
MEM medium  were incubated in  flat-bottomed plates with  20 #l unheated serum  (final 
dilution  1:10)  from S.  mansoni-infected  patients  or normal  subjects,  and  100  #1  MEM 
containing 7.5 X  107 platelets from normal subjects (8).  In both assays, the percentage of 
cytotoxicity was evaluated by microscopic examination after 24-48 h at 37°C in 5% CO2 
atmosphere.  For inhibition experiments,  eosinophils or platelets were preincubated with 
various concentrations of ascitic fluids (dilution  1:100) or purified  mAbs for 60 min at 
+4°C  for eosinophils  and  37°C  for platelets.  The  results  of inhibition  by  BB10 were 
compared with results obtained with cells incubated with medium or control IgM. 
Rosette Assays.  For the  study of Fc receptors,  a  rosette assay using aldehyde-treated 
erythrocytes coated with human IgE or human IgG was performed as previously described 
(5).  Cell suspensions (30 #l of a solution containing 4  x  106 cells/ml in MEM/FCS) were 
incubated with  30 ul of Ig- or BSA-sensitized erythrocytes (2  X  10S/ml  in  MEM/FCS). 
After centrifugation  at  100 g  at  +4°C  for  10 rain,  the  ceils  were further  incubated  at 
+4°C  for  30  min.  For  complement  (CR1)  receptors,  one  volume  (30  #1)  of sheep 
erythrocytes bearing  human  C3b (ESC3b),  prepared  according to a  previous  technique 
(21) with  10S/ml  HBSS, was added to an equal volume of cell preparations (4 x  106/ml 
in  HBSS).  After centrifugation at  100 g  for 5  rain at +20°C, the sedimented cells were 
incubated  for  30  min  at  37°C.  In  both  assays  (FcR  or  CR1),  the  pellets  were  gently 
resuspended  and the  percentage of rosette  forming cells was evaluated microscopically, 
as previously described (5).  For inhibition experiments,  the various cell populations were 
preincubated with the mAbs for 60 rain at +4°C before rosette formation, similar to the 
cytotoxicity assay. 
Binding ofRadiolabeled BBIO and IgE.  Purified  IgM fractions of the mAbs BB10 or 
control G 10-54, and rat or human IgE were radioiodinated by the chloramine T  technique 
(22). Two hundred #g of BBI0 or G10-54, or IgE were labeled with 0.2 mCi of ~2~I-Na 
to asp  act of 0.5-0.7  #Ci/#g.  Radioiodinated  antibodies  were stored  at  +4°C  in  PBS 
containing  1%  BSA. For the quantitation  of BB 10 binding,  the various cell populations 
were incubated at  107/ml for 60 min at +4°C, except for ptatelets (10q/ml for 60 rain at 
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of 200 #1 PBS-BSA 1%. After washings, the cell suspensions were centrifuged at 8,500 g 
for 2 min through  1 ml of 25% sucrose, and the radioactivity of the pellets was measured 
in a gamma scintillation spectrometer (Inter technique CG4000, Plaisir, France). 
The specificity of the binding of radiolabeled BBI0 was determined at each point and 
for all  cell  populations  by subtracting  the  cpm  bound  to  cells  after  addition  of equal 
concentrations of labeled, control IgM G 10-54. In some experiments, cells were incubated 
with  a  50-fold  excess  dose  of cold  BB10  before  addition  of radiolabeled  BB10.  The 
inhibition  ranged between  71  and  87%  (78.5  +  0.6%  for eosinophils and  80 +  8%  for 
platelets; n, 6 experiments),  which indicated between  13 and 30% of nonspecific binding. 
For competition  experiments,  rat  eosinophils,  human  monocytes (106  cells/tube),  or 
human platelets (8 x  10V/tube) were incubated with various concentrations (100 ug-5 t~g 
per tube) of unlabeled reagents (control G 10-54, BB 10, or aggregated IgE) for 30 min at 
+4°C  (except  for platelets,  room  temperature).  The  radiolabeled  reagents  were  then 
added (1  ttg BB10/tube,  60 min at +4°C,  or  1 #g IgE/tube,  90 min at +4°C, or room 
temperature  for platelets).  The cell suspensions  were centrifuged over 20%  sucrose,  as 
above. In all cases, the background radioactivity of controls without cells was subtracted. 
Molecular  Weight Determination  of the Molecules Eluted from  BBIO or I~,E Affinity  Col- 
umn.  Membrane proteins were solubilized by treating the cells (75 ×  10  ~ platelets or x 
108 U937/ml) with a nonionic detergent mixture consisting of 0.5% NP-40 in PBS (0.14 
M NaCI; 0.01  M  PO4, pH 7.4) in the presence of 2 mM PMSF and 2 mM EDTA. After 
a  30  rain  incubation  at +4°C,  the  insoluble  material  was removed by centrifugation at 
22,000 g  for 40  min.  The detergent  extracts were then radiolabeled  with  125I by using 
Iodogen (Pierce Chemical Co., Rockford, IL). 
For isolation of the molecule reactive with BB 10, the lysates were passed over a CNBr- 
activated Sepharose  4B column (1.5 ml) to which the mAb BB10, at a concentration of 
0.870  mg/ml,  was coupled.  Controls included cell  lysates passed over Sepbarose  4B to 
which G10-54 purified IgM was coupled and also control supernatants without cells.  The 
colmnns were first washed with  PBS (plus NP-40, PMSF, and EDTA) and the adsorbed 
material was eluted with 3 M NaSCN. Fractions of 0.5 ml were collected and dialyzed. 
For isolation of the IgE reactive molecules, 35-70 ttl of the detergent extract were first 
agitated on a  test tube rotator with BSA immunosorbent for 30 min at 20°C. Then the 
extracts  were passed over a  CNBr-activated  Sepharose  column (200 /~1) to which  1 mg 
human myeloma IgE was coupled, for  16 hr at +4°C.  The affinity column was washed 
with PBS containing 0.5%  NP-40, 2 mM PMSF, and 2 mM EDTA. Bound, radiolabeled 
material was eluted with 3 M NaSCN by fractions of 32 ul, dialyzed, and concentrated by 
centrifugation on Centricon (Amicon Corp., Danvers, MA). 
SDS-PAGE  (13%  weight/vol  polyacrylamide)  was  then  performed.  The  gels  were 
stained  with  silver  in  the  case  of material  eluted  from  BB10  column or submitted  to 
autoradiography  in  the  case  of IgE  immunosorbent.  All  the  techniques  used  for  this 
molecular weight determination  have been adapted from previous papers (23-24). 
Expression of the Results.  All results were presented  as mean  +  SEM. Student's t test 
for paired experiments was used to compare the values obtained in the presence and in 
the absence of BB 10. 
Results 
Characteristics of BB lO Fluorescence Staining.  For practical reasons (storage of 
cells fixed on PLL-coated slides), the IFSA was used both to screen the hybridoma 
supernatants  and also to make a  survey of cell types reactive with BB 10.  Intense 
membrane  fluorescence  was  detected  on  eosinophils  (human  and  rat)  and  on 
macropbages (both  human  alveolar and  rat peritoneal).  The  staining of human 
eosinophils was more pronounced  with degranulated  hypodense blood and tissue 
purified cells, than with the fully granulated normodense populations (Fig.  1 and 
Table  1).  Intensity of fluorescence  staining  of blood monocytes was inferior  to 
that  observed  for  human  alveolar  macrophages  (Table  I).  These  results  and CAPRON ET  AL.  77 
FIGURE 1.  Binding of BB10 to human eosinophils (a and b) "hypodense" cells; (c and d) 
"normodense" eosinophils coated on PLL-slides; (a and c) immunofluorescence slide assay 
(IFSA); (b and d) interferential contrast microscopy.  The less granulated ("hypodense")  eosin- 
ophils (arrows)  stained more brightly than the fully  granulated ones. 
especially the variation in the intensity of fluorescence staining between normo- 
dense and hypodense eosinophils and  between monocytes and alveolar  macro- 
phages,  suggested  a  coincident  distribution  of the  BB10 antigen  and  the  low 
affinity FceR2.  In  addition,  quantitative  analysis of various cell populations by 
FMF  both  confirmed  the  qualitative  analysis  by IFSA  and  suggested  that  the 
BB10 antigen  was present only on a significant proportion  of hypodense eosin- 
ophils from hypereosinophilic patients and monocytes and platelets from normal 
subjects.  An  increase  in  the  percent  of positive  cells  was  detected  in  alveolar 
macrophages, whereas neutrophils were negative. Among the rat peritoneal cells, 
eosinophils  and  a  large  proportion  of  macrophages  were  positive,  whereas 
lymphocytes were negative (Table I, Fig. 2). Moreover, a preliminary experiment 
revealed that  the  polyclonal mouse antisera  obtained  before the  hybridization 
could  induce  high  levels  of inhibition  of  IgE  rosettes  formed  by  hypodense 
human eosinophils, indicating some relationship with the IgE Fc receptors. 
Inhibition  of IgE-dependent  Cytotoxicity.  To investigate the effect of BB 10 on 78  MONOCLONAL  ANTIBODY  TO  THE  SECOND lgE  Fc  RECEPTOR 
"FABLE  1 
Reactivity of BB l O with Various Cell 
Populations by Immunofluorescence 
IFSA* (in- 
Cells used  tensity of  FMF* (percent 
fluores-  positive cells) 
cence) 
Human cells: 
Hypodense blood eosinophils  +++  37.6 + 8.9 
Normodense blood eosinophils  +  10.6 4- 5.5 
Hypodense lung eosinophils  +++  ND 
Neutrophils  4-  4.6 4- 0.5 
Blood monocytes  +  9.4 4- 2.1 
Alveolar macrophages  +++  16.9 4- 0.1 
Platelets  ND  10.8 4- 6.4 
Rat peritoneal cells: 
Eosinophils  +++  17.3 _+ 1.9 
Macrophages  +++  90.9 4- 0.3 
Lymphocytes  +  2.9 4- 0.2 
* The various cell preparations  were deposited onto PLL-coated micro- 
scope slides and successively incubated with the purified IgM fractions 
of BB 10 or G 10-54 (t 00 #g/ml), and with fluorescein-conjugated anti- 
mouse IgM antibodies (1:20). The results are estimated according to the 
intensity of membrane fluorescence. 
* Cells were incubated in suspension with BB10 or G10-54 at 200/*g/ml 
for 30 rain at +4°C and further stained  with fluorescein-conjugated 
anti-mouse IgM antibodies (percent positive cells 4- SEM). On all cell 
populations, control GI 0-54 antibodies gave results <5%. 
the IgE-dependent effector function of eosinophils, inhibition experiments were 
performed  by  preincubation  of  hypodense  eosinophils  (purified  from  blood 
leukocytes of highly  hypereosinophilic  patients  according  to  their  low  density) 
with medium or with various concentrations of BB 10 or control G 10-54. Ascitic 
fluids  (1:100)  or  decreasing  concentrations  (200-10  #g/ml)  of  purified  IgM 
fractions were incubated with eosinophils for 60 rain at +4°C before addition to 
schistosomu]a  and  antischistosome  IgE  antibodies;  there  was  no  washing.  As 
shown  in  Fig.  3,  preincubation  of hypodense  eosinophils  with  ascitic  fluids  of 
BB10  induced  a  high  level  of inhibition  of IgE-dependent  cytotoxicity,  and  a 
dose-dependent inhibition  was obtained with the purified IgM fraction of BB 10. 
Student's  t  test  for paired  experiments  revealed  highly  significant  results  (p < 
0.001, n,  16 experiments), except in the case of the lower dose of purified BB10. 
Since the IgE-dependent cytotoxicity of both human eosinophils and platelets 
was recently shown  to  be inhibited  at  the  same level with  polyclonal  anti-FceR 
antibodies (5,  9,  10),  we performed inhibition  experiments of platelet-mediated 
killing by BB10  (Fig.  4).  When  human  platelets  were preincubated  with ascitic 
fluid of BB10 before addition of anti-S, mansoni immune sera and schistosomula 
targets,  a  very significant  inhibition  of the  killing  was obtained  compared with 
that of platelets incubated with medium (Student's t test for paired experiments: 
p <  0.01, n, 9 experiments). Similarly to eosinophils, a dose-dependent inhibition 
of IgE-mediated  killing  was  also  obtained  with  the  purified  IgM  fractions  of 
BB10 (p <  0.0001,  n, 9 experiments), whereas control IgM GI 0-54 did not lead CAPRON  ET  AL.  79 
FIGURE 2.  Binding of BBI0 (upper  curve) or  control G10-54  (lower curve) to  various cell 
populations by flow cytometry. (a) Hypodense eosinophils from a patient with HES; (b) from 
a  patient with  filarial  infection.  (c)  Normal  human  platelets;  (d)  normal  rat  macropbages. 
Vertical, relative cell number; Horizontal, relative fluorescence intensity. Values given in the 
corners are the percent positive cells in the peak for one representative experiment. 
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FIGURE  3.  Inhibitory role ofBB10 on lgE-dependent killing mediated by human eosinophils. 
Hypodense eosinophils were preincubated for 60 rain at +4°C, either with medium or with 
ascitic fluids (AF), or purified IgM fractions of BB10 or control G10-54.  Without washings, 
the cells were added  to schistosomula and IgE-containing immune sera and the cytotoxicity 
was measured after 48 h contact. 
to any significant inhibition of the cytotoxicity. In  both  cases,  eosinophils and 
platelets,  microscopical observations  revealed that  BB10  was  not cytotoxic for 
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purified IgM fractions of control IgM G10-54 or BB10. Schistosomula and unheated anti-S. 
mansoni immune sera were then added and the percentage of cytotoxicity was measured after 
24 h contact. 
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FIGURE 5.  RoLe of  BB10  on  lgE  rosette  formation  by  eosinophils.  Human  hypodense 
eosinophils were incubated for 60 min at +4°C with control lgM or with BB10 (AF, ascitic 
fluids or  IgM  fractions), before the addition of lgE-coated erythrocytes (2  ×  108/ml).  The 
percentage of rosette  forming eosinophils was estimated on suspensions after staining with 
Discombe's diluent. 
Role of BB lO on Surface Receptors.  The expression of such ADCC mechanisms 
required  functional  Fc  receptors  able  to  bind  specific antibodies.  Among  the 
various factors potentially involved in ADCC, we investigated the inhibitory role 
of BB10 on several membrane receptors, including Fct or Fc~, receptors and C3 
receptors. Rosette assays were therefore performed with human eosinophiis and 
sheep erythrocytes coated with  IgE immunoglobulins,  to investigate the inhibi- 
tory role of BB10 on the IgE Fc receptors. As shown in Fig. 5, the IgE rosettes 
formed by hypodense human  eosinophils were inhibited either  in the presence 
of ascitic fluids or decreasing concentrations  of purified  BB10 (Student's t test CAPRON  ET  AL. 
TABLE  II 
Effect of BBlo on Various Surface Receptors 
81 
Percent positive with:  Percent 
Leukocyte type  Assay 
BB10  Control G10-54  inhibition 
Eosinophils:  IgG rosettes  36.3 +_ 3.8  35.4 +_ 5.5  0 
IgG-dependent cytotoxicity  84.6 +  6.6  81 _  4  0 
C3b rosettes  43 _  17  46.5 +  6.4  7.6 
Neutrophils:  lgG rosettes  77.7 +  10.6  69.5 _  13.1  0 
The cells (purified human blood eosinophils or neutrophils) were preincubated with BBI0 or control 
G10-54 for 30-60 rain at +4°C before addition to indicator erythrocytes in the rosette assays or to 
parasite targets and heat-inactivated immune serum in the cytotoxicity assay. The IgG rosettes were 
performed by using sheep erythrocytes coated with human normal IgG. Sheep erythrocytes bearing 
Csb  were  prepared  by  sequential  deposition  of  C3b  by  fluid-phase and  cell-bound  amplification 
convertases. 
for paired  experiments:  p  <  0.0001,  n,  21  experiments;  except for the  lower 
dose: p <  0.05, n, 8 experiments). 
Because these  results suggested a  direct  inhibitory  role of BB10 on  the  Fcc 
receptors of eosinophils, it was interesting to know the effect of BB 10 on other 
surface  receptors.  When  human  eosinophils  were preincubated  with  BB10  or 
with  control  G10-54,  no difference in  the  proportion  of IgG-rosettes  was de- 
tected. Similarly, no inhibition of the IgG-mediated, eosinophil-dependent cyto- 
toxicity was observed. In addition, the preincubation of eosinophils or neutrophils 
with BB 10 did not lead to any significant inhibition of rosettes with C3b or IgG- 
coated erythrocytes, respectively (Table II). 
Moreover, comparison experiments between the inhibitory role of BB 10 and 
other anti-IgE Fc receptor antisera were performed on rat eosinophils and mast 
cells (Table III). Since BB 10 could bind to rat eosinophils (Table I), its inhibitory 
role on  rat  eosinophil  FccR could be confirmed  by inhibition  of IgE  rosettes, 
whereas the IgE rosettes formed by rat peritoneal mast cells were not significantly 
inhibited  (Table  III).  Similar  results  were  obtained  with  the  polyclonal  goat 
antiserum,  already known  to inhibit  the  IgE receptors of human  lymphocytes, 
monocytes, and eosinophils (11).  In contrast,  the mAb directed against the rat 
basophil leukemia Fc~R could only inhibit IgE rosettes formed by rat mast cells. 
Binding oflodinated BBIO and IgE.  The binding  of radioiodinated  BB10 to 
various human  blood cell populations was first studied.  As shown in Figure 6a, 
one could notice that  only hypodense eosinophils were able to specifically bind 
labeled  BB10,  whereas  no  significant  binding  was  detected  on  normodense 
eosinophils  or  on  neutrophils  (three  patients  were  studied  in  each  case).  In 
parallel,  experiments  performed  on  normal  human  platelets  revealed  specific 
binding of BB 10, similar to hypodense eosinophils (Fig. 6 b). 
Experiments of competition of binding between BB 10 and IgE were performed 
on  purified  eosinophils  from  normal  rats  to  obtain  the  more  homogeneous 
populations. As shown in Table IV, when rat eosinophils were preincubated with 
unlabeled BB 10, a dose-dependent inhibition  of binding of both radioiodinated 
BB10  and  IgE  was  observed.  Very  high  levels  of  inhibition  were  similarly 
observed when the cells were preincubated with aggregated  IgE before incuba- 
tion with iodinated BB 10 or IgE. Experiments performed on human monocytes 82  MONOCLONAL  ANTIBODY TO  THE  SECOND  IgE  Fc  RECEPTOR 
TABLE  III 
Comparison of Various Anti-lgE Fc Receptor Antisera on Rat Eosinophils 
and Mast Cells 
Ceils incubated with: 
Percent lgE rosettes with: 
Rat Eosinophils  Rat mast cells 
Control  14.2 _+ 1.2  69.2 -+ 4.3 
BB 10 (ug/ml) 
200  3.7 + 0.5*  65.5 + 2.5 
100  2.5 -- 0.9*  56.2 -+ 3.2 
50  4.3 -  0.9*  73.8 + 3.8 
10  5.3 +_ 1.6"  66.0-+ 3.8 
Polyclonal goat antiserum (final 
dilution) 
1/10  3.0 __ 1.0"  67.1 + 7.4 
1/25  3.2 _+ 1.2*  68.9 _+ 2.2 
1/50  11.2 _  6.2  64.3 _+ 5.2 
Monoclonal anti-RBl, (ug/ml) 
5  11.3 _+ 0.6  8.2 + 3.5* 
1  10.9 _+ 0.7  8.0 +  1.0" 
0.5  12.3+ 1.4  22.6_+ 5.1" 
0.1  14.6 _+ 0.9  46.5 + 2.5* 
Rat eosinophils or mast cells were preincubated (60 min at +4°C) with BBl0, 
with goat antiserum directed against a B lymphoblastoid cell line, or with anti- 
RBL antibodies (purified  mAb directed against the IgE Fc receptor of RBL 
[25]). The percent of IgE rosettes  was compared  on purified eosinophils or 
mast cells from  normal rats incubated either with the controls  (respectively 
G10-54, normal goat serum, or medium) or with the antireceptor antibodies. 
Results are the mean -+ SEM of at least four experiments. 
* Inhibition  was significant at p < 0.001. 
* Inhibition  was significant at p < 0.02. 
and platelets clearly confirmed the  inhibitory role  of BB10  on  the  binding of 
radioiodinated human  IgE. 
Comparison  by SDS-PAGE Analysis  of the Platelet  Proteins  Eluted from  BBIO  or 
IcE Affinity Columns.  The detergent lysates from purified human platelets were 
passed over insolubilized mAb BB10 and eluted with high salts. As seen in Fig. 
7A  (lane  1),  several  bands can  be  identified in  this affinity-enriched material, 
which are not present in the controls without cell lysate (Fig.  7A, lane 2).  Four 
bands were observed at Mr of 32,000, 43,000, 45,000, and 94,000.  In addition, 
a  nonspecific band was detected at 67,000. 
In the case of the labeled platelet extract eluted from IgE affinity column (Fig. 
7B, lane 1), a  very similar pattern was obtained in autoradiographic SDS-PAGE 
analysis,  with  four  bands  at  31,500,  43,000,  45,000,  and  97,000.  In  both 
immunosorbents, the 43,000 band was the most prominent band. Fig.  7B (lane 
2) shows an autoradiograph of radiolabeled U937  (FcER+) extract eluted from 
IgE column. The  two  main bands detected at  23,000  and 43,000 were  similar 
to those already reported (24).  The  control FceR- U937 cells submitted to the 
same procedure did not show any labeled material (Fig. 7 B, lane 3). CAPRON  ET  AL.  83 
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binding to  hypodense eosinophils, A;  normodense eosinophils, (-1; and neutrophils, O.  (b) 
Specific binding to normal human platelets, I. 
Discussion 
In this study we describe an mAb able to inhibit the IgE-dependent killing of 
parasite  targets  by  human  eosinophils and  platelets.  The effector function of 
these  cells  was  previously  shown  to  require  a  specific  binding  site  for  IgE 
immunoglobulins with  a  relatively  low affinity  for  the  ligand  (9).  This  mAb, 
BB10, is an IgM immunoglobulin and was obtained after immunization of mice 
with hypodense eosinophils. Such eosinophils were purified from the blood of 
highly hypereosinophilic patients (with the hypereosinophilic syndrome or para- 
sitic diseases, for instance), or from tissues (lungs), according to their abnormally 
low density (2, 3, 6). This eosinophil subpopulation was recently shown to exhibit 
increased  IgE-dependent  cytotoxicity  against  schistosomula  targets  compared 
with that of eosinophils with normal density (normodense) (5). 
Mice were therefore immunized by hypodense blood eosinophils and boosted 
with hypodense lung eosinophils from the same patient, who was shown to give 
high levels of IgE-dependent cytotoxicity against schistosomula targets (5).  With 
the IFSA procedure used to screen the hybridoma supernatants and control the 
specificity of purified antibodies, the strong membrane fluorescence with BB10, 
the  negativity  of  unrelated  IgM  mAbs  (anti-Echinococcus multilocularis),  the 84  MONOCLONAL  ANTIBODY  TO  THE  SECOND  IgE  Fc  RECEPTOR 
TABL~  IV 
Competition Experiments Between BB IO and IgE 
Preincubated 
Cell types  with unlabeled: 
Cell-bound radioactivity (cpm/tube) 
after incubation with: 
125I-BB  10  125I-IgE 
Rat eosinophils: 
Human monocytes: 
Human platelets: 
Control IgM  9142 4-  1790  5101 4- 388 
BB10  (× 100)  1451  4- 342*  (84)*  1460 4- 252*  (71) 
(× 50)  4119 4- 847 §  (55)  2350 4- 377*  (54) 
(x25)  7194 4- 1672  (21)  3854 4- 780  (24) 
(x  10)  10020 4- 1528  (0)  4266 4- 607  (16) 
IgE  (× 50)  2259 4- 356*  (75)  1897 4- 317*  (63) 
(× 25)  2037 4- 466*  (77)  1778 4- 983*  (65) 
(× 10)  1944 4- 359*  (79)  21524-930 ~  (58) 
(× 5)  2147 4- 255*  (76)  1538 4- 979*  (70) 
Medium  4870 4- 230 
BBI0  (× 50)  ND  1356 4- 489*  (72) 
IgE  (× 20)  854 4- 490*  (82) 
Medium  11352 4- 1359 
BB10  (x50)  ND  5526 4- 687 §  (51) 
IgE  (× 10)  2083 +  813"  (81) 
The various cell populations (106/tube for eosinophils and monocytes and 8 x  107 platelets/tube) 
were preincubated with various concentrations of unlabeled reagents (from  100- to 5-fold excess 
labeled products) before incubation with ~5I-BB 10 or the respective rat or human J25I-lgE myeloma 
protein (1  #g/tube). After centrifugation over sucrose, the radioactivity of the pellets was deter- 
mined. The cell-bound radioactivity was estimated by subtracting the background cpm obtained in 
control tubes without cells. 
* Significant inhibition at p <  0.01  level. 
* Parentheses indicate the percent inhibition. 
§ Significant inhibition at p <  0.05 level. 
decrease in  fluorescence intensity between hypodense and  normodense eosino- 
phils,  the  negativity  of neutrophils  and  the  inhibitory  role of mouse  immune 
serum (before the hybridization) on IgE rosette formation by eosinophils allowed 
us  to  consider  the  possibility  that  BB10  was  an  mAb  directed  against  the 
eosinophil Fc~ receptor. FMF analysis, moreover, confirmed that the percentage 
of cells stained by BB10 was closely related to the percentage of cells expressing 
IgE receptors by the rosette assay, as previously reported (5,  11). 
The specificity of BB 10 for Fc~R was settled by several types of evidence. First, 
the high  level and the dose-dependence of inhibition  of IgE-mediated  effector 
function of human hypodense eosinophils suggested that the epitope recognized 
by BB10 was involved in the mechanism of cell activation for killing. 
However, the evidence was not sufficient to include Fc~ receptors, since other 
membrane  proteins known to play a  role in cell adhesion  to targets  might also 
be involved  in  this  mechanism.  Therefore,  three  results  confirmed  the  direct 
effect of BB 10 on the IgE receptor: (a) the parallel inhibitory function of BB10 
on IgE rosette formation and on IgE-mediated killing by eosinophils, (b) the lack 
of inhibition of other surface receptors such as eosinophil IgG or C3b receptors, 
or neutrophil  IgG  receptors,  and  (c) a  similar  inhibitory  role  in  IgE-mediated 
killing by human  platelets. This last point deserves some consideration.  Indeed, CAPRON ET  AL.  85 
FIGURE  7.  (A) SDS-PAGE analysis  of platelet lysate  eluted from BBI0 affinity columns (lane 
1); control without cells (lane 2). (B) SDS-PAGE analysis  of platelet (lane I), U937 Fc~R  + (lane 
2), and U937 Fc~R- (lane 3) extracts eluted from lgE affinity columns. Apparent Mr of the 
bands are indicated by arrows (A and B, lane I). 
the inhibitory role of polyclonal antibodies in IgE-dependent cytotoxicity medi- 
ated by eosinophils (5) and platelets (10) bad previously revealed that a common 
antigenicity was  shared  between  the  IgE receptors  on  human eosinophils and 
platelets (9).  However,  the  two  killing mechanisms seemed different, since,  in 
contrast to the eosinophil situation, adherence of platelets to their targets was 
not required (25).  Therefore, it is likely that the inhibitory role of BB10 acted 
through  the  IgE  receptors,  rather  than  by  an  indirect  effect  on  the  killing 
mechanism itself. The parallel inhibition by an mAb of IgE-dependent effector 
function  of  eosinophils  and  platelets  precisely  confirmed  the  presence  of  a 
common structure between the Fc~R of human eosinophils and platelets, Fc~R2. 
Moreover, preliminary results with human monocytes indicated similar inhibition 
of IgE-dependent function against parasites and IgE binding by BB 10. 
In addition, the comparison between the effect of BB10 and two other anti- 
Fc~R antibodies on mast cells and eosinophils indicated that the epitope recog- 
nized by BB10 and by the polyclonai goat anti-FcER lymphocyte antiserum was 
also present on rat eosinophits, but did not interfere with IgE binding to rat mast 
cells. On  the other hand, the anti-RBL mAb that could inhibit IgE binding to 
RBL and rat mast cells (26), did not inhibit IgE binding to rat eosinophils. These 
findings  suggest  the  existence  of a  second  receptor  for  IgE  on  eosinophils, 
platelets, and monocytes, which is distinct from FceR1  present on basophils and 
mast cells (27). 
Experiments of binding of radiolabeled BB 10 were performed on various cell 86  MONOCI.ONAL  ANTIBODY  TO  THE  SECOND  IgE  Fc  RECEPTOR 
populations  to  quantify  the  epitope  recognized  by  BB10  and  investigate  the 
crosscompetition between BB 10 and IgE. The present results showed that similar 
levels of specific binding were obtained with hypodense eosinophils and normal 
platelets, but not with normodense eosinophils. Since BB 10 is a pentameric IgM 
molecule, the precise numbers of binding sites for BB10 could not be measured 
by this  technique;  however, experiments  now in  progress with  the  monomeric 
form of BB10 revealed a K~ of 10~)/M for both eosinophils and platelets, and a 
number of binding sites around 105/cell for eosinophils and 103/cell for platelets, 
which are close to the numbers of IgE receptors evaluated by using radiolabeled 
IgE (9) (Jouault,  T.,  manuscript  in preparation).  Competition  experiments also 
suggested that not only BB 10 exhibited a strong inhibitory effect on IgE binding, 
but that  preincubation  of cells with aggregated  IgE seemed to saturate  the  Fce 
receptor and to inhibit the subsequent binding of BB 10. This fact has to be taken 
into consideration in the case of human eosinophils from patients with high levels 
of circulating IgE immunoglobulins, a situation where the Fc~R have been shown 
to be occupied by cytophilic IgE (15).  Indeed in these cases no binding of BB10 
could be detected (data not shown). 
SDS-PAGE analysis of the  molecules eluted from  BB10 affinity column  was 
performed with human  platelets because of their availability in large quantities 
and  high  degree of purity.  As recently shown for a  mAb anti-B cell FceR (28), 
several bands could be identified  by this  technology.  The  similarities  between 
the SDS-PAGE patterns of platelet extracts eluted from BB10 or IgE immuno- 
sorbents suggest that the proteins retained on BB10 could very well be derived 
from  the  IgE  receptor.  Their Mr are closely related  to protein  components of 
the IgE receptor on WIL-2WT (23) and on the macrophage-like  U937 cell line 
(24).  Preliminary  results  on  radiolabeled  eosinophil  extracts  showed a  pattern 
similar to that observed with  U937 FceR+ with two major bands at 23,000 and 
45,000-50,000.  Experiments  are  now  in  progress  to  compare  platelet  and 
eosinophil  IgE receptors with the structure of the rat macrophage  IgE receptor 
identified by using lgE and crosslinking reagents (29). 
Whereas  the inhibition  of IgE receptors by a  polyclonal antiserum  indicated 
that  FceR  on  lymphocytes,  macrophages,  eosinophils,  and  platelets  were  all 
antigenically related and differed from those on basophils (9-11), BB 10 did not 
seem  to  inhibit  IgE  receptors  on  two  B  cell  lines,  WIL  2  or  RPMI  8866 
(Spiegelberg, H. L., Scripps Clinic,  La Jolla,  CA and  Delespesse, G., University 
of Manitoba,  Winnipeg,  Canada,  personal  communications).  These results sug- 
gest  that  the  FceR on  lymphocytes,  al.ready  individualized  from  others  by its 
higher affinity for IgE (10S/M) could also be structurally different.  The lack of 
inhibition  of B lymphocyte FcER by BB10 could be due to either the increased 
affinity of this receptor for IgE (which is 10 times higher than affinity for BB10) 
or to a structural  difference. In this respect, no clearcut evidence is supplied on 
the  identity  of  FceR  on  BEc  and  macrophages  (11),  and  it  would  be  very 
interesting to compare BBI 0 with other mAbs that can inhibit Fce receptors on 
B lymphocytes or B ceil lines (30). 
Finally, according to the survey of cells functionally reacting with BB10, this 
mAb seemed different from other mAbs directed against human eosinophils. Eo 
1,  which,  in  contrast  to  BB10,  reacted  with  neutrophils  and  lymphocytes, did CAPRON ET  AL.  87 
not react with platelets and had few functional effects (31). On the other hand, 
Eo 1-7 all bound to neutrophils also (32). One interesting characteristic between 
three of these mAb (Eo 4, 5, and 6) that detected membrane antigens strongly 
expressed on hypodense cells, and BB10, was that they were all of IgM isotype. 
This seems to represent a  common feature of mAbs with regulatory functions 
and implies that multivalent binding of the appropriate receptors is a prerequisite 
in the triggering of functional effects (33). 
Besides  the  difficulties  encountered  in  studies  on  FccR-bearing  eosinophils 
because of their presence on a small proportion of cells, the fact that these cells 
are only present in the blood of patients with hypereosinophilia, and also because 
of  their  low  affinity  for  IgE,  it  is  worthwhile  to  recall  that  cytophilic  IgE 
immunoglobulins were recently detected on blood eosinophils and,  to a greater 
extent, on  lung eosinophils (15).  This was a  clear demonstration  that these FcE 
receptors were not an in vitro artefact, but had sufficient affinity to bind IgE in 
vivo, especially those present on lung eosinophils. Moreover, the lung eosinophils 
were shown to participate to cytolysis of lung epithelial cells (7).  Therefore, the 
presence of Fc~R might  represent one marker  of pathological eosinophils, and 
BB10 could be used as an  interesting  reagent  to identify those cells in  human 
pathology and to investigate their susceptibility to various therapeutics in order 
to prevent the tissue lesions induced by eosinophils. 
Summary 
An  IgM  mAb  (BB10)  was produced  by immunization  of mice  with  human 
eosinophils purified according to their abnormal low density ("hypodense" cells), 
and previously shown  to exhibit increased  IgE-dependent  antiparasite  cytotox- 
icity.  This  BB10 antibody,  selected for positive fluorescence staining  of hypo- 
dense blood or  lung  eosinophils  and  low or negative  staining  of normodense 
eosinophils or neutrophils,  could strongly inhibit  IgE-dependent cytotoxicity of 
human  eosinophils  and  platelets.  The  specificity for  the  IgE  Fc receptor  was 
suggested by the high  levels of inhibition of IgE rosettes formed by eosinophils 
after incubation with the purified IgM fraction of BB 10, whereas other receptors 
(Fc3'R, CR1)  were not affected.  On  the  other  hand,  BB10, able to inhibit  rat 
eosinophil FceR, did not react with the IgE Fc receptor on mast cells or basophils. 
A  technique  using  radioiodinated  BB10  allowed  us  to  quantify  the  specific 
binding of BB10 to human  eosinophils and platelets.  Competition  experiments 
revealed a crossinhibition between the binding of BB 10 and IgE, suggesting the 
specificity of BB 10 for the IgE binding site of eosinophil, platelet, and monocyte 
FceR.  Three  proteins  having  extrapolated Mr of 32,000,  43,000-45,000,  and 
97,000  were found in  the platelet extract eluted from a  BB10 or from an  IgE 
immunosorbent column. These findings confirm the similarities between IgE Fc 
receptors on human  eosinophils,  platelets,  and  macrophages,  already observed 
with polyclonal antibodies directed against the B lymphocyte Fc¢ receptor. They 
suggest, moreover, that the mAb BB10 can represent a good reagent for further 
investigations on the structure and the functions of this IgE Fc receptor (FceR2). 
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